NPPA Directs Strict Monitoring of Implementation of TMR on 137 Anti-Cancer Drugs
Fact cardPublished: · Updated:
Source: PIB (Press Information Bureau) · Read the original ↗
Summary
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed strict monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, notified vide Gazette Order dated 17 October 2026, with revised prices effective from 9 November 2026.
Key facts for Prelims
- Body: the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed strict monitoring of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs.
- Legal basis: the TMR was notified by Gazette Order dated 17 October 2026, with revised prices effective 9 November 2026. Violations may attract overcharging proceedings under the Drugs (Prices Control) Order (DPCO), 2013.
- Latest revised price lists: based on company submissions up to 11 November 2026, they are available on the NPPA website and the Pharma Sahi Daam app/portal.
- Compliance duty: manufacturers, retailers, dealers, stockists, hospitals and medical institutions must follow the revised prices. They must display updated price lists prominently at their premises and on their websites.
- Role of State Drug Controllers (SDCs): they monitor compliance so that benefits of revised MRPs reach patients. They must submit Action Taken Reports to NPPA by 16 November 2026.
- Grievance channels: the Pharma Sahi Daam app/portal, NPPA helpline 1800-111-255, and email monitoring-nppa[at]gov[dot]in. Complaints can cover overcharging, shortage or non-availability.
Related topics
- DPCO 2013, the National List of Essential Medicines, and the Department of Pharmaceuticals' regulatory role.
Topics: GS2
All current affairs of 13 November 2026 → · UPSC Current Affairs